Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone vs placebo plus abiraterone in first-line mCRPC
2024-511144-86-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Olaparib + abiraterone with Placebo + abiraterone (2 arms). Primary endpoint: Radiological progression-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-511144-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511144-86-00.